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Abstract
In recent years, genetic analyses of congenital deficiencies of three anticoagulant proteins, antithrombin, protein
C (PC) and protein S (PS), in East Asian patients with venous thromboembolism (VTE) have greatly increased. The
PS-K196E mutation is often identified in the Japanese population with an allelic frequency of 0.86 %, and a total of
approximately 10,000 Japanese are estimated to be homozygotes. The heterozygotes show PS anticoagulant
activities ranging from 40 to 110 %, and 16 % lower mean anticoagulant activity than that in wild-type individuals.
Specific assay methods to identify carriers of this mutation have recently been developed. The mutation carriers are
at risk of thrombosis during pregnancy but do not appear to be at risk for adverse pregnancy outcomes. To
promote future research into this mutation and its relation to thrombosis, a thrombosis-prone mouse strain with
the PS K196E mutation has been developed. We found the PS-K196E mutation and the heterozygous PS-deficiency
in mice caused increased VTE, but did not cause aggravation of ischemic stroke, unlike factor V Leiden mutation.
Importantly, the PS-K196E mutation is only identified in Japanese. This suggests that although East Asian
populations including Japanese, Chinese, and Koreans are geographically and genetically close, the PS-K196E
mutation seems to be Japanese-specific, suggesting that the mutation is a recent occurrence and fixed within
the Japanese population. Some recurrent genetic mutations predisposing to VTE have been reported in
Chinese and Korean populations. Although the genetic background for VTE is known to differ between
populations with Caucasian descent and East Asian populations, some of the recurrent mutations differ
even within the East Asian populations.
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Background
Venous thromboembolism (VTE) is a worldwide burden
associated with death and disability. The R506Q muta-
tion in factor V (FV), also known as the FV Leiden
(FVL) mutation, is well known as an established genetic
risk factor for VTE in individuals of Caucasian descent
[1, 2]. The FVL mutation was identified in 1994; in 1995
we attempted to identify the FVL mutation in the
Japanese population, but failed due to its absence in East
Asian populations [3]. To identify the genetic variants of
VTE in the Japanese population, we performed a nation-
wide collaborative study of 5 hospitals supported by the
Ministry of Health, Labour and Welfare of Japan. In this
study, we genotyped the 5 genetic variations and found
that a Lys196-to-Glu substitution in the protein S (PS)
gene (PS-K196E, rs 121918474, c.586A>G, also known
as PS Tokushima, PS-K155E in the mature protein num-
bering) was a genetic risk factor for VTE with an odds
ratio of 4.72 [4, 5]. This finding was published in 2006.
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Historically, the PS-K196E mutation was identified simul-
taneously in 1993 and 1994 by two independent Japanese
groups in families with or without VTE [6, 7]. Individuals
with the PS-K196E mutation in families without VTE
showed PS anticoagulant activity within a normal limit,
suggesting the mutation was a neutral polymorphism [6],
whereas individuals with the mutation in another family
with VTE showed low PS anticoagulant activity, suggesting
PS-K196E was causative for VTE [7, 8]. Therefore, whether
the mutation would be a risk for VTE was debatable. A
subsequent our study, however, revealed that both observa-
tions were correct, because the heterozygous carriers of this
mutation in a general population showed anticoagulant
activities ranging from 40 up to 110 %, that were substan-
tially overlapped with those of wild-type individuals [9]. In
this short review, we will summarize the history of the PS-
K196E mutation and discuss the similarities or differences
of the genetic background for VTE among East Asians.
Review
Prevalence and unique geographical profile of PS-K196E
mutation
Three case-control studies of VTE independently indicated
that the PS-K196E mutation is a genetic risk factor for
VTE in the Japanese population (odds ratio = 3.74–8.56)
(Table 1) [4, 10, 11]. In the Japanese population, a total of
81 heterozygotes have so far been identified among
4686 individuals enrolled in four studies [4–6, 10, 11]
and two public genome databases ([12], http://www.geno-
me.med.kyoto-u.ac.jp/SnpDB/index.html), yielding an al-
lele frequency of 0.86 % for the PS-K196E mutation, and
indicating that approximately 1 of 58 Japanese is a hetero-
zygous carrier. We thus estimate that approximately 1 of
every 13,000 Japanese individuals is homozygous for the
mutant allele. The Japanese population was approxi-
mately126 million on 1 January 2015, meaning that as
many as 9440 individuals are homozygotes for the PS-
K196E mutation. Thus, a substantial number of Japanese
carry the mutant PS 196E allele, as a heterozygote or
homozygote, and are likely at risk of developing VTE. So
far, no homozygotes have been identified in the general
population, but three homozygotes have been found
among 258 VTE patients, yielding an incidence of 1.2 %
among patients with VTE [10, 13].
The risk of developing VTE conferred by PS-K196E
thus appears to be fairly mild (odds ratio: 3.74–8.56).
Accordingly, some VTE patients have been found to bear
PS-K196E along with other deleterious genetic mutations,
such as PC-K193del, PC-R221W, and PC-V339M, indicat-
ing that carriage of the PS-K196E mutation concomitant





























































n.d. Korean Kim et al., 2014 [16]
aGenetic analysis was performed in VTE patients with anticoagulant activity of less than 2.5 percentile of the local reference intervals. bGenetic analysis was
performed in population individuals with anticoagulant activity of less than 1 percentile of the population. n.d. not determined
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with other predisposing mutations for thrombosis facili-
tates the onset of VTE [13].
Although East Asians, including Japanese, Chinese, and
Koreans, are geographically and genetically close, the
PS-K196E mutation has so far been identified only in
Japanese and not in Chinese and Koreans, even in the
VTE patients [14–17]. Thus, PS-K196E mutation
seems to be Japanese-specific, suggesting that the
mutation is a recent occurrence and fixed within the
Japanese population.
Anticoagulant activity of heterozygous carriers of PS-
K196E mutation
We performed a phenotype-genotype analysis in individuals
with or without PS-K196E mutation in the Japanese general
population (n = 1862), and found that heterozygotes
(n = 34) showed anticoagulant activities ranging from 40
to 110 %, and the anticoagulant activities between hetero-
zygotes and wild-types were substantially overlapped [9].
Thus, the anticoagulant activity assay widely used for the
identification of PS deficiency is not a good tool to identify
the PS-K196E carriers. The mean PS anticoagulant activity
in heterozygotes, however, was 16 % lower than that in
wild-type individuals. Acquired PS deficiency is associated
with nephrotic syndrome or pregnancy. These conditions
may further promote the PS-activity reduction in muta-
tion carriers, thereby enhancing the risk for VTE.
DVT and adverse pregnancy outcome in pregnant women
with PS-K196E mutation
The PS-K196E mutation appears to be a genetic risk
factor for deep vein thrombosis (DVT) during pregnancy
[18]. Among 18 patients with DVT during pregnancy
and the postpartum period, we identified 4 DVT patients
with PS mutation and 1 DVT patient with PC mutation
[18]. Among the 4 DVT patients with PS mutation, 2
were heterozygous for the PS-K196E mutation with
DVT onset of 27 and 10 weeks, respectively. None car-
ried mutations in the antithrombin gene. All patients
with the genetic mutation showed DVT at the first or
second trimester and none showed DVT at the third
trimester or postpartum period. It is well known that the
PS anticoagulant activity is decreased in pregnancy.
Since the genetic mutation accelerates DVT onset, DVT
onset at the early stage of pregnancy in patients with the
PS-K196E mutation would be reasonable.
Adequate maternal-fetal circulation is important for a
successful pregnancy outcome, and disturbance of circula-
tion may result in serious adverse pregnancy outcomes,
such as severe preeclampsia, placental abruption, intrauter-
ine fetal death (IUFD), or severe fetal growth restriction
(FGR). The causes of these adverse pregnancy outcomes
are not known, but they may be associated with abnormal
placental vasculature and disturbances of hemostasis.
In a previous report, we tried to address whether
adverse pregnancy outcomes in Japanese parturients are
associated with the PS-K106E mutation or rare genetic
mutations in three anticoagulant genes: PS, PC, and an-
tithrombin [19]. We enrolled 330 Japanese patients with
adverse pregnancy outcomes and divided them into 233
patients with two or more miscarriages and 114 patients
with FGR and/or IUFD; 17 patients belonged to both
groups. In this cohort, the PS-K196E mutation was identi-
fied in 4 out of 233 patients with two or more miscarriages
and 2 out of 114 patients with FGR and/or IUFD. The fre-
quencies of the PS-K196E mutation in these patient
groups were not different from that in the Japanese gen-
eral population. Therefore, the PS-K196E mutation does
not confer a significantly increased risk of these adverse
pregnancy outcomes. Our results were compatible to
those of a recent large prospective cohort study in Canada
in which carriage of FVL or the prothrombin G20210A
mutation did not increase the risk for the adverse preg-
nancy outcomes of pregnancy loss, small for gestational
age, preeclampsia, or placental abruption [20].
In our study, rare nonsynonymous mutations in the
three anticoagulant genes were found in only 3.3 % (11
out of 330) of patients with adverse pregnancy outcomes,
indicating that carriers with rare mutations were not
dominant in patients [19]. Therefore, although the small
fraction of patients with adverse pregnancy outcomes may
be explained by the rare variations in the three anticoagu-
lant genes, these rare mutations are not likely a major
cause of the development of adverse pregnancy outcomes.
Screening methods for PS-K196E mutation carriers
As described above, the anticoagulant PS activity is not a
reliable measure for the identification of PS-K196E
mutation carriers, and thus until recently the only accur-
ate detection assay was DNA analyses such as direct
sequence analysis, restriction fragment length polymorph-
ism analysis, or the TaqMan genotype discrimination
method. More recently, however, two plasma assay
methods were developed to distinguish the carriers
from the wild-type individuals.
We developed monoclonal antibodies specific to the
PS K196E mutant using GANP transgenic mice that
show an increased frequency of somatic mutations in
the Ig-variable region and are suitable for high-affinity
antibody production [21]. We constructed a sandwich
enzyme-liked immunosorbent assay (ELISA) using one
of the monoclonal antibodies for detecting plasma
samples of individuals with the PS K196E mutation [21].
This assay is a simple, efficient, and accurate tool for the
detection of PS-K196E carriers. The ELISA assay can
detect the PS K196E mutant in plasma and can be iden-
tified in carriers even though they are under warfarin
treatment or during pregnancy.
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Another assay has been developed using the specific
activity of PS for the discrimination of heterozygotes
from the wild-types [22]. Since individuals with PS type
II deficiency who are carriers of the PS-K196E mutation
show the reduced PS activity with normal antigen limits,
the specific activity obtained as the ratio of the activity
level divided by the antigen level would be reduced to
around 0.5. Actually, the mean PS specific activity of the
PS-K196E heterozygote carriers was 0.64 [22]. This assay
can distinguish individuals with the PS type II deficiency
who are carriers of the PS-K196E mutation from wild-
type individuals. However, individuals with low specific
activity do not always have the PS K196E mutation and
may have other missense mutations.
Mice bearing PS-K196E mutation
Guidelines for establishing pathogenic causality for rare
genetic variants have recently been published [23]. They
suggest that the strongest evidence for causality comes
from disruption of the candidate gene in a model organ-
ism which recapitulates the pathology in humans. To
evaluate the thrombogenicity of the PS-K196E mutation,
we generated PS-K196E knock-in mice and analyzed
their phenotypes in comparison with heterozygous PS-
deficient mice and factor V-R504Q knock-in mice (FVL
mice) [24]. Plasma from PS-K196E homozygous mice
had 67 % of normal APC cofactor activity, similar to a
purified recombinant murine PS-K196E mutant that had
49 to 60 % of normal PS activity. Mouse C4BP does not
contain the PS-binding ß-chain, which is a pseudogene
in mice, so interpretation of the APC cofactor activity is
uncomplicated by C4BP considerations.
The susceptibility of PS-K196E mice to VTE was
assessed in multiple models, including (i) an electrolytic
inferior vena cava model of venous thrombosis that
produces a non-occlusive and consistent thrombus in
the presence of constant blood flow, (ii) a tissue factor-
initiated pulmonary thromboembolism model, and (iii) a
polyphosphate-initiated pulmonary thromboembolism
model [24]. All thrombotic parameters in these throm-
bosis models, including mortality, showed that the PS-
K196E mutation in mice caused increased VTE, very
similar to the heterozygotes for PS deficiency and to the
murine FVL mutation. Heterozygotes for the PS-K196E
mutation gave a milder thrombotic phenotype than ho-
mozygotes. These results demonstrate a causal link be-
tween the PS-K196E mutation and thrombophilia,
strongly supporting the notion that the PS-K196E muta-
tion is a human genetic risk factor for VTE. PS K196E
mice would be valuable for disease-related studies in
which FVL mice have been examined.
Currently, the extent to which the PS-K196E mutation
or PS deficiency are risk factors for arterial occlusive
diseases is not clear. To explore the arterial occlusive
risk of these PS genetic variations, we used a cerebral
focal ischemia-reperfusion model. We found no exacer-
bation of ischemic stroke in PS-K196E mice and hetero-
zygous PS-deficient mice [24]. We previously observed
that FVL mice showed increased infarct volumes com-
pared with wild-type mice [25]. Our studies suggest that
PS-K196E mutation in mice does not cause aggravation
of ischemic stroke, unlike factor V Leiden mutation.
Thrombophilic mutations in Chinese and Korean
populations
Genetic analyses in patients with VTE and in the general
populations have been reported from China and Korea as
well. The PC Arg189Trp mutation (PC-R189W, c.565C>T,
PC-R147W in the mature protein numbering) and the PC
Lys193del mutation (PC-K193del, c.574-576del, PC-
K151del in the mature protein numbering) were reported to
be risk factors for VTE in the Chinese population, with odds
ratios of 5.10–7.30 and 2.93, respectively (Table 1) [26–28].
Both R189 and K193 residues are located on a 21-amino-
acid peptide, with 8 basic Lys and Arg amino acids on it, in
the C-terminal part of the PC light chain. The PC-R189W
and K193del mutations are present in 0.9 and 2.4 % of the
Chinese population, respectively [26, 28]. The former muta-
tion was not identified in 767 Japanese, but the later was
identified in 10 out of 767 Japanese including one ho-
mozygote [http://www.genome.med.kyoto-u.ac.jp/SnpDB/
index.html], and both mutations were identified in Japanese
and Korean patients with VTE. Both heterozygotes are asso-
ciated with reduced anticoagulant activity and a relatively
normal PC antigen level, indicating type II deficiency. The
recombinant PC-R189W mutant shows normal amidolytic
and proteolytic activities in the absence of cofactors, but
exhibits about 3 times lower affinity for binding to EPCR
[29]. The recombinant PC-K193del mutant has approxi-
mately 2–3 fold impaired anticoagulant activity in the
presence of PS [29]. Individuals with the PC-K193del mu-
tation show normal amidolytic activity of PC but reduced
anticoagulant activity [13, 30].
In the genetic analysis in the Korean population, the PC
Arg211Trp (PC-R211W, PC-R169W in the mature protein
numbering) and Met406Ile (PC-M406I, PC-M364I in the
mature protein numbering) mutations, both of which cause
type I PC deficiency, were identified in 2.8 and 1.8 % of the
VTE patients, and 0.2 and 0 % of the Korean population
(Table 1), respectively [16]. Both PC mutations have been
identified in Japanese VTE patients [30], but not in the
Japanese Human Genetic Variation Database [http://
www.genome.med.kyoto-u.ac.jp/SnpDB/index.html]. In the
antithrombin gene, the Arg79Cys and Ser158Pro mutations
(AT-R79C and AT-S158P, AT-R47C and AT-S116P in the
mature protein numbering, respectively) have been identi-
fied in 0.4 and 0.2 % of Korean VTE patients, respectively
(Table 1). Both mutations have previously been identified in
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Japanese VTE patients with heparin-binding defects. Since
both were also present in the Korean general population,
they would confer weak risk for VTE (Table 1), if any. We
previously demonstrated that the antithrombin deficiency
with the heparin-binding defects conferred a lower VTE
risk than type I deficiency [31], and this finding was
compatible with the Korean VTE study.
Conclusion
We identified a PS-K196E mutation as a mild genetic risk
factor for VTE. The mutation is specific to the Japanese
population and not present in Chinese and Koreans. We
generated a mouse line carrying the PS K196E mutation.
The thrombosis phenotypes observed in the PS K196E
mice indicated a strong link between the PS-K196E muta-
tion and thrombosis. Compared with the frequencies of
genetic mutations among East Asian populations, many
genetic mutations predisposing to VTE, except for the PS
K196E mutation, are commonly distributed, but their
frequencies differ among East Asian countries.
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